Zaragoza

• An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) Recruiting
  2024-514972-42-00 5 2025-02-25 Thyroid eye disease
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade … Recruiting
  2024-513317-12-00 5 2025-02-05 Pancreatic cancer
• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of … Recruiting
  2024-513356-15-00 5 2024-12-30 Acquired Blepharoptosis
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour
• A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime … Recruiting
  2023-509807-34-00 4 2024-08-12 Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementi
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized … Recruiting
  2023-508441-41-00 6 2024-07-08 Bacteriemia producida por P. aeruginosa.
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-507039-39-00 5 2024-03-22 Moderate to Severe Plaque Psoriasis
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Recruiting
  2022-503091-89-00 4 2024-02-15 Delayed graft function
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w … Recruiting
  2025-522542-40-00 5 2026-06-19 Acute Ischemic Stroke
• STUDY TO FIND OUT WHETHER A SHORTER ANTIBIOTIC TREATMENT (7 DAYS) IS AS EFFECTIVE AND SAFE AS THE USUAL ONE (14 DAYS) IN PATIENTS WITH AN IN … Recruiting
  2025-523120-53-00 11 2026-06-10 Graft pyelonephritis in kidney transplant recipients
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Recruiting
  2025-523461-17-01 5 2026-06-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• Optimising TREATment for severe Gram-Negative Bacterial infections. Recruiting
  2025-521476-65-00 6 2026-05-28 Severe Gram-Negative Bacterial infections
• A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg Recruiting
  2025-523739-20-00 5 2026-05-14 Hypercholesterolemia
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus

Showing 73–96 of 527 trials